Syra Health Corp. Class A Common Stock (SYRA) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Syra Health Corp. Class A Common Stock (SYRA) es una empresa del sector Healthcare valorada en 0.
Ultimo analisis: 16 mar 2026Syra Health Corp. Class A Common Stock (SYRA) Resumen de Asistencia Médica y Tuberías
Syra Health Corp. delivers health education, population health management, and digital health solutions, targeting mental health facilities and government agencies. With a focus on telehealth and digital transformation, Syra operates in the evolving healthcare services sector, marked by a negative profit margin and high beta.
Tesis de Inversión
Syra Health Corp. operates in the growing healthcare services market, with a focus on digital health and telehealth solutions. The company's diverse service offerings, including health education, population health management, and mental health services, position it to capitalize on the increasing demand for integrated healthcare solutions. Key value drivers include the expansion of its Syrenity telehealth platform and the growth of its digital health solutions. However, the company's negative profit margin of -12.4% and high beta of 3.96 indicate significant financial risk. The company's small market capitalization also presents liquidity concerns. Investors should carefully weigh the growth potential against the financial risks before considering an investment in Syra Health.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Syra Health Corp. operates with a market capitalization of $0.00B, indicating its status as a micro-cap company.
- The company's P/E ratio is -1.40, reflecting its current lack of profitability.
- Syra Health Corp. has a negative profit margin of -12.4%, highlighting challenges in achieving profitability.
- The company's gross margin is 29.8%, suggesting potential for improved profitability with efficient cost management.
- Syra Health Corp. has a high beta of 3.96, indicating significant volatility compared to the broader market.
Competidores y Pares
Fortalezas
- Diverse service offerings including health education, population health management, and digital health.
- Focus on telehealth and digital health solutions.
- Strong relationships with mental health hospitals and government agencies.
- Development of proprietary Syrenity telehealth platform.
Debilidades
- Negative profit margin indicating financial challenges.
- Small market capitalization and limited financial resources.
- High beta indicating significant volatility.
- Limited brand recognition compared to larger competitors.
Catalizadores
- Ongoing: Expansion of Syrenity telehealth platform to increase market reach and service offerings.
- Ongoing: Growth in digital health solutions to capitalize on the increasing adoption of digital healthcare technologies.
- Ongoing: Strategic partnerships with healthcare organizations to expand service delivery and customer base.
- Ongoing: Development and launch of new health education programs to improve patient outcomes and engagement.
- Ongoing: Expansion of healthcare staffing solutions to address the growing shortage of healthcare professionals.
Riesgos
- Potential: Intense competition from larger, more established players in the healthcare services industry.
- Potential: Regulatory changes and healthcare reform that could impact the company's business model.
- Potential: Economic downturn that could reduce demand for healthcare services.
- Potential: Cybersecurity threats and data breaches that could compromise patient data and damage the company's reputation.
- Ongoing: Negative profit margin indicating financial challenges and potential liquidity issues.
Oportunidades de crecimiento
- Growth opportunity 1: Expansion of Syrenity Telehealth Platform: Syra Health's development of Syrenity, an on-demand telehealth platform for mental health services, presents a significant growth opportunity. The telehealth market is projected to reach $55.6 billion by 2027, driven by increasing demand for remote healthcare services. By expanding the features and reach of Syrenity, Syra Health can capture a larger share of this growing market and improve access to mental health services. Timeline: Ongoing.
- Growth opportunity 2: Digital Health Solutions: Syra Health's digital health solutions, including digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps, offer substantial growth potential. The digital health market is expected to reach $379 billion by 2024, fueled by the increasing adoption of digital technologies in healthcare. By developing innovative digital health solutions tailored to the needs of its clients, Syra Health can drive revenue growth and enhance its competitive position. Timeline: Ongoing.
- Growth opportunity 3: Healthcare Workforce Solutions: Syra Health's healthcare staffing solutions address the growing demand for qualified healthcare professionals. The healthcare staffing market is projected to reach $44.7 billion by 2027, driven by shortages of nurses, physicians, and other healthcare workers. By providing flexible and cost-effective staffing solutions, Syra Health can help healthcare organizations meet their workforce needs and improve patient care. Timeline: Ongoing.
- Growth opportunity 4: Population Health Management Services: Syra Health's population health management services, including analytics as a service, epidemiology, and health equity analytics solutions, offer a valuable service to healthcare organizations seeking to improve patient outcomes and reduce costs. The population health management market is expected to reach $69.2 billion by 2027, driven by the increasing focus on value-based care and preventative medicine. By providing data-driven insights and solutions, Syra Health can help healthcare organizations optimize their population health management strategies. Timeline: Ongoing.
- Growth opportunity 5: Health Education Services: Syra Health's health education services, including medical communications, patient education, and healthcare training, address the critical need for effective communication and education in healthcare. The health education market is expected to grow as healthcare organizations increasingly recognize the importance of patient engagement and adherence. By providing engaging and informative health education programs, Syra Health can help improve patient outcomes and satisfaction. Timeline: Ongoing.
Oportunidades
- Expansion of Syrenity telehealth platform to capture a larger share of the telehealth market.
- Growth of digital health solutions to meet the increasing demand for digital healthcare technologies.
- Expansion of healthcare staffing solutions to address the growing shortage of healthcare professionals.
- Leveraging population health management services to capitalize on the increasing focus on value-based care.
Amenazas
- Intense competition from larger, more established players in the healthcare services industry.
- Regulatory changes and healthcare reform that could impact the company's business model.
- Economic downturn that could reduce demand for healthcare services.
- Cybersecurity threats and data breaches that could compromise patient data and damage the company's reputation.
Ventajas competitivas
- Diverse service offerings provide a comprehensive suite of healthcare solutions.
- Focus on digital health and telehealth solutions positions the company for future growth.
- Strong relationships with mental health hospitals and government agencies.
- Proprietary Syrenity telehealth platform offers a competitive advantage.
Acerca de SYRA
Syra Health Corp., established in 2020 and headquartered in Carmel, Indiana, is a healthcare services company that provides a suite of solutions, including health education, population health management, behavioral and mental health services, healthcare workforce solutions, and digital health services. The company's health education services encompass medical communications, patient education, and healthcare training programs. Its population health management services include analytics as a service, epidemiology, and health equity analytics solutions, designed to improve patient outcomes and reduce healthcare costs. Syra Health is also developing Syrenity, a telehealth platform focused on delivering mental health services on-demand. Furthermore, the company offers healthcare staffing solutions and digital health solutions, including digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. Syra Health serves a diverse clientele, including mental health hospitals, government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers, positioning itself as a versatile partner in the healthcare ecosystem.
Qué hacen
- Provides health education services, including medical communications and patient education.
- Offers population health management services, such as analytics and epidemiology solutions.
- Develops Syrenity, an on-demand telehealth platform for mental health services.
- Provides healthcare staffing solutions to hospitals and healthcare organizations.
- Offers digital health solutions, including digital transformation and cloud security.
- Serves mental health hospitals, government agencies, and managed care entities.
Modelo de Negocio
- Generates revenue through health education services provided to healthcare organizations.
- Earns revenue from population health management services, including data analytics and consulting.
- Monetizes its Syrenity telehealth platform through subscription fees and service charges.
- Derives income from healthcare staffing solutions provided to hospitals and clinics.
Contexto de la Industria
Syra Health Corp. operates within the healthcare services industry, which is experiencing significant growth due to factors such as an aging population, increasing prevalence of chronic diseases, and advancements in technology. The industry is characterized by intense competition, with companies vying for market share in areas such as telehealth, digital health, and population health management. Syra Health's focus on integrated healthcare solutions and its diverse service offerings position it to compete effectively in this dynamic landscape. However, the company faces challenges from larger, more established players with greater resources and brand recognition.
Clientes Clave
- Mental health hospitals and organizations seeking comprehensive healthcare solutions.
- Government agencies requiring population health management and health education services.
- Integrated health networks looking for digital health and telehealth solutions.
- Managed care entities seeking to improve patient outcomes and reduce healthcare costs.
- Pharmaceutical manufacturers requiring medical communications and patient education programs.
Finanzas
Gráfico e información
Precio de la acción de Syra Health Corp. Class A Common Stock (SYRA): Price data unavailable
Últimas noticias
-
Syra Health Q4 EPS $(0.01) Up From $(0.08) YoY, Sales $1.734M Down From $2.000M YoY.
benzinga · 12 mar 2026
-
Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026
prnewswire.com · 12 mar 2026
-
Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com · 5 mar 2026
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · 20 may 2024
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para SYRA.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para SYRA.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de SYRA en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Últimas Noticias
Syra Health Q4 EPS $(0.01) Up From $(0.08) YoY, Sales $1.734M Down From $2.000M YoY.
Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026
Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results
12 Health Care Stocks Moving In Monday's Pre-Market Session
Último análisis de Syra Health Corp. Class A Common Stock
Liderazgo: Gregory R. Alexander
Unknown
Information about Gregory R. Alexander's background is not available in the provided context. Therefore, his career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive biography.
Historial: Information about Gregory R. Alexander's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to evaluate his performance as CEO.
Información del mercado OTC de SYRA
The OTC Other tier represents the lowest tier of the OTC market, indicating that Syra Health Corp. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in Syra Health Corp.
- Lower trading volumes and wider bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight on the OTC Other tier increases the potential for fraud and manipulation.
- Limited access to capital markets can hinder the company's ability to raise funds for growth and expansion.
- The OTC Other tier may attract speculative trading, increasing the risk of sudden price swings.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Check for any legal or regulatory issues involving the company.
- Understand the risks associated with investing in OTC stocks.
- Company incorporation in 2020 suggests a relatively new business.
- Headquarters located in Carmel, Indiana.
- Provides a range of healthcare services, including health education and digital health solutions.
- Serves mental health hospitals and government agencies.
Lo Que los Inversores Preguntan Sobre Syra Health Corp. Class A Common Stock (SYRA)
¿Cuáles son los factores clave para evaluar SYRA?
Evaluar SYRA implica revisar los fundamentales, el consenso de analistas y los factores de riesgo. Fortaleza clave: Diverse service offerings including health education, population health management, and digital health.. Riesgo principal a monitorear: Potential: Intense competition from larger, more established players in the healthcare services industry.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de SYRA?
El MoonshotScore califica a SYRA de 0 a 100 en salud financiera, impulso del mercado y factores de riesgo. Puntuaciones superiores a 70 indican calificaciones más altas, 50-70 moderadas y por debajo de 50 calificaciones más bajas. Se recalcula diariamente. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de SYRA?
Los precios de SYRA se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre SYRA?
La cobertura de analistas para SYRA incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en SYRA?
Las categorías de riesgo para SYRA incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from larger, more established players in the healthcare services industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de SYRA?
La relación P/E para SYRA compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está SYRA sobrevalorada o infravalorada?
Determinar si Syra Health Corp. Class A Common Stock (SYRA) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de SYRA?
Syra Health Corp. Class A Common Stock (SYRA) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide further insights.